LHLeila Haddad

Leila Haddad

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Leila Haddad has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Liver microbiome composition associates with histological severity and PNPLA3 genotype in metabolic dysfunction-associated steatotic liver disease

    by Maria Florencia Mascardi, Rosario Taussig, Ivan Privitera Signoretta, Barbara Suarez, Sebastian Marciano, Paola Casciato, Adrian Narvaez, Leila Haddad, Adrian Carlos Gadano, Alberto Penas-Steinhardt, et al.

    BACKGROUND Metabolic dysfunction-associated steatotic liver disease (MASLD) is a systemic immunometabolic disorder rapidly increasing worldwide, affecting nearly 38% of adults. Gut dysbiosis and host genetic factors, such as PNPLA3 I148M variant, modulate disease development and progression. Through the gut-liver axis, increased intestinal permeability enables microbial translocation to the liver, promoting inflammation and metabolic disruption. However, the composition and functional potential of the hepatic microbiome remain poorly characterized. Understanding its relationship with histological injury and genetic susceptibility may provide novel mechanistic insights. We hypothesized that the hepatic microbiome composition and function are associated with histological severity and PNPLA3 genotype in this disease. AIM To characterize the hepatic microbiome and assess its association with histological severity and PNPLA3 genotype. METHODS This cross-sectional observational study included 30 patients with MASLD from a tertiary care hospital. Liver tissue underwent shotgun metagenomic sequencing. Histological severity was assessed using the NAFLD Activity Score (NAS). PNPLA3 genotype was determined by PCR. Differential abundance and functional enrichment analyses were performed using MaAsLin2. Somatic variants were identified using Mutect2. Correlation networks were constructed using Spearman's correlation coefficients. RESULTS Patients with advanced histological injury (NAS ≥5) and PNPLA3 I148M carriers showed a trend toward higher somatic mutational load and a markedly reduced microbial abundance. Analyses revealed broad compositional shifts across bacterial, fungal, viral, and eukaryotic taxa, affecting both commensal and context-dependent pathobiont lineages. Pseudomonas species were enriched, whereas Siphoviridae phages were depleted in advanced disease and PNPLA3 I148M carriers. Functional analysis revealed enrichment of pathways related to nutrient transport and metabolic stress adaptation, while TonB-associated functions were enriched in advanced liver injury but depleted in PNPLA3 I148M carriers. Network analysis identified Sphingomonas leidyi as a keystone node associated with hexosamine metabolism. Salmonella enterica abundance positively correlated with somatic variant burden, suggesting a link between microbial signatures and genomic instability. Histological progression and the risk PNPLA3 genotype were accompanied by marked topological simplification, reflecting less resilient community structures. CONCLUSIONS The hepatic microbiome in MASLD is a low-biomass, polymicrobial ecosystem shaped by the host genetic background. Its functional activity, taxonomic composition and system architecture bidirectionally relate to liver DNA instability and the severity of histological damage.

  • Open Access

    Do changes in inflammatory markers predict hepatocellular carcinoma recurrence and survival after liver transplantation?

    by Lucas José Caram, Francisco Calderon, Esteban Masino, Victoria Ardiles, Ezequiel Mauro, Leila Haddad, Juan Pekolj, Jimena Vicens, Adrian Gadano, Eduardo de Santibañes, et al.

    Lucas José Caram, Francisco Calderon, Esteban Masino, Victoria Ardiles, Ezequiel Mauro, Leila Haddad, Juan Pekolj, Jimena Vicens, Adrian Gadano, Eduardo de Santibañes, Martín de Santibañes. Ann Hepatobiliary Pancreat Surg 2022;26:40-6. https://doi.org/10.14701/ahbps.21-094


  • Open Access

    P-55 QUALITY OF LIFE IMPROVES IN PATIENTS WITH OR WITHOUT CIRRHOSIS AFTER HEPATITIS C CURE WITH DIRECT-ACTING ANTIVIRAL AGENTS

    by Lucrecia Garcia Olveira, Sebastián Marciano, Leila Haddad, Monica Fabiola Vasquez Palacios, Diego Giunta, Adrian Gadano

  • Open Access

    Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV‐infected patients in a real‐life cohort from Latin America

    by Manuel Mendizabal, Leila Haddad, Patricia E. Gallardo, Alejandro Ferrada, Alejandro A. Soza, Raul Adrover, Edmundo Aravena, Juan P. Roblero, Jhon Prieto, Claudia Vujacich, et al.

    Information about the use of ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin (OBV/PTV/r/DSV ± RBV) in real‐clinical practice in Latin America is scarce. We aimed to confirm safety and effectiveness of OBV/PTV/r/DSV ± RBV therapy in real‐world setting. We analyzed a cohort of patients with genotype 1 infection treated with OBV/PTV/r/DSV ± RBV. Data on demographics, clinical features, safety, and virological response were retrospectively collected from 21 centers in Latin America. A total of 96 patients received OBV/PTV/r/DSV, associated with RBV in 68% of the cases. Most were genotype 1b (80%), 56 (58%) had cirrhosis, and 45 (47%) failed prior HCV treatment. Adverse events occurred in 62% of patients. The most common adverse events were pruritus (21%), hyperbilirubinemia (17%), and asthenia (17%). Five patients discontinued therapy prematurely due to hepatic decompensation, three of them were Child‐Pugh B at baseline and one patient died due to multi‐organ failure. Follow up HCV‐RNA 12 weeks after completion of therapy was evaluated in all the patients and sustained virologic response rate was 97%. No virologic breakthrough was detected. Our study confirms that OBV/PTV/r/DSV treatment is highly effective in patients with chronic HCV without cirrhosis or with Child‐Pugh A cirrhosis in non‐European populations. Adverse events were often mild and rarely led to treatment discontinuation except for patients with Child‐Pugh B cirrhosis or with previous history of hepatic decompensation. These results can support the development of public strategies to expand the access of OBV/PTV/r + DSV and other DAAs combinations in order to reduce the burden of HCV infection in our region.